2. Metabolic Enzyme/Protease
  3. Angiotensin-converting Enzyme (ACE)
  4. CV 5975

CV 5975 is an orally active angiotensin converting enzyme (ACE) competitive inhibitor with a rabbit lung ACE IC50 of 3.1 nM and Ki values of 2.6 nM. CV 5975 inhibits ACE in plasma, aorta, kidney, and brain, intensifying inhibition with repeated administration. CV 5975 inhibits Angiotensin I (HY-P1032)-induced pressor responses and ileum contraction, and augments bradykinin-induced ileum contraction and depressor responses. CV 5975 reduces blood pressure via ACE-independent mechanisms, with sustained action across multiple hypertensive and normotensive animal models, intensified by repeated dosing or Hydrochlorothiazide (HY-B0252) co-administration. CV 5975 can be used for the research of hypertension.

For research use only. We do not sell to patients.

CV 5975

CV 5975 Chemical Structure

CAS No. : 100277-62-1

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

CV 5975 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

CV 5975 is an orally active angiotensin converting enzyme (ACE) competitive inhibitor with a rabbit lung ACE IC50 of 3.1 nM and Ki values of 2.6 nM. CV 5975 inhibits ACE in plasma, aorta, kidney, and brain, intensifying inhibition with repeated administration. CV 5975 inhibits Angiotensin I (HY-P1032)-induced pressor responses and ileum contraction, and augments bradykinin-induced ileum contraction and depressor responses. CV 5975 reduces blood pressure via ACE-independent mechanisms, with sustained action across multiple hypertensive and normotensive animal models, intensified by repeated dosing or Hydrochlorothiazide (HY-B0252) co-administration. CV 5975 can be used for the research of hypertension[1][2][3][4].

IC50 & Target[1]

ACE

 

In Vitro

CV 5975 (40 g; 3.5-29 h) Chemoenzymatic kinetic resolution with lipase PN produces (R)-4 (64% ee) that is converted to CV-5975 via mesylation, SN2 reaction, and deprotection, with an overall 25% yield from (R)-4[1].
CV 5975 (40 g; 48 h) Baker's yeast-mediated asymmetric reduction of α-oxoester 3 produces (R)-4 (61% ee) in 46% yield, which is suitable for the synthesis of CV-5975[1].
CV 5975 (10-8 M; 60 min) potently inhibits crude angiotensin converting enzyme from albino male rabbit lungs with an IC50 of 3.1 × 10-9 M, demonstrating far greater potency than its three stereoisomers[2].
CV 5975 (20 min) potently and competitively inhibits partially purified rabbit lung ACE, with an IC50 of 3.1 × 10-9 M, a Ki of 2.6 × 10-9 M, and a high-affinity steady-state Ki* of 4.4 × 10-12 M[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CV 5975 Related Antibodies
In Vivo

CV 5975 (0.3-3 mg/kg; i.v. or p.o.; single dose) potently and durably inhibits Angiotensin I-induced pressor responses in male Sprague-Dawley rats, with >90% inhibition maintained for at least 2 hours after intravenous administration of 0.3 mg/kg and for up to 7 hours after oral administration of 3 mg/kg, showing the longest duration of activity among tested piperidyl derivatives[2].
CV 5975 (10 mg/kg; p.o.; single dose) produces a mild, significant hypotensive effect in normotensive Wistar Kyoto rats that persists for 10 hours[3].
CV 5975 (1-10 mg/kg; p.o.; daily for 2 weeks) exerts dose-dependent, sustained antihypertensive effects in spontaneously hypertensive rats, with intensified potency and duration upon repeated dosing, and produces marked, tissue-wide ACE inhibition that correlates with blood pressure reduction[3].
CV 5975 (1-10 mg/kg; p.o.; single dose) produces a potent, long-lasting, dose-dependent antihypertensive effect in 2-kidney, 1-clip renal hypertensive rats, with a maximum blood pressure reduction of 65 mmHg that persists for over 24 hours at the 10 mg/kg oral dose[3].
CV 5975 (1-10 mg/kg; p.o.; single dose) exerts a dose-dependent antihypertensive effect in 1-kidney, 1-clip renal hypertensive rats, with a significant blood pressure reduction lasting over 10 hours at the 10 mg/kg oral dose[3].
CV 5975 (1-10 mg/kg; p.o.; single dose; daily for 2 weeks) produces a mild, dose-dependent antihypertensive effect in hyporeninemic DOCA/salt hypertensive rats, with no enhanced efficacy upon repeated daily dosing[3].
CV 5975 (0.3-1 mg/kg; p.o.; single dose) produces a long-lasting antihypertensive effect in 2-kidney, 1-clip renal hypertensive dogs, reducing systolic and diastolic blood pressure by approximately 40 mmHg at the 1 mg/kg dose[3].
CV 5975 (0.3-1 mg/kg; p.o.) potently inhibits Angiotensin I-induced pressor responses in normotensive beagle dogs at 0.3 and 1 mg/kg p.o., with over 90% inhibition and longer lasting effects than enalapril[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (male, 300-400 g)[2]
Dosage: 0.3 mg/kg (i.v.); 3 mg/kg (p.o.)
Administration: i.v. or p.o.; single dose
Result: Inhibited angiotensin I-induced pressor responses by 96% at 10 minutes, 99% at 30 minutes, 93% at 60 minutes, and 91% at 120 minutes after intravenous 0.3 mg/kg administration.
Exhibited the longest duration of ACE inhibition among tested piperidyl derivatives, with recovery to 50% of control taking over 4 hours after intravenous 0.3 mg/kg administration.
Inhibited angiotensin I-induced pressor responses by 70% at 20 minutes, 84% at 1 hour, 91% at 3 hours, 88% at 5 hours, and 84% at 7 hours after oral 3 mg/kg administration.
Animal Model: Wistar Kyoto rats (male, 20 to 22 weeks old)[3]
Dosage: 10 mg/kg
Administration: p.o.; single dose
Result: Slightly but significantly reduced mean arterial blood pressure, with maximum reductions of 9 mmHg at 5 hr, 8 mmHg at 7 hr, and 10 mmHg at 10 hr.
Returned blood pressure to pre-drug levels by 24 hr post-administration.
Animal Model: Spontaneously hypertensive rats (male, 20 to 22 weeks old)[3]
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: p.o.; single dose; daily for 2 weeks
Result: Reduced blood pressure dose-dependently by 10 to 35 mmHg, with maximum effects at 5 to 10 hr that lasted more than 24 hr.
Intensified antihypertensive potency and duration upon repeated dosing, with maximum effects observed on day 7; 1 week after treatment cessation, blood pressure remained significantly lower than controls (202 mmHg at 1 mg/kg, 203 mmHg at 3 mg/kg, 202 mmHg at 10 mg/kg) and returned to control levels by 2 weeks post-cessation.
Inhibited ACE activity in all tested tissues (plasma, aorta, kidney, lung, brain) after repeated daily dosing for 1 week.
Animal Model: Wistar rats (male, 6 weeks old initially, used 4 to 6 weeks after 2-kidney, 1-clip renal hypertension surgery, systolic blood pressure 160 to 240 mmHg)[3]
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: p.o.; single dose
Result: Caused a dose-related, marked, sustained decrease in blood pressure; the maximum effect of ~65 mmHg was seen at 7 to 10 hr post-dose, and blood pressure remained below pre-drug levels for more than 24 hr.
Animal Model: Wistar rats (male, 6 weeks old initially, used 4 to 6 weeks after 1-kidney, 1-clip renal hypertension surgery, systolic blood pressure 160 to 240 mmHg)[3]
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: p.o.; single dose
Result: Reduced blood pressure dose-dependently; at 10 mg/kg, the effect was observed from 3 hr post-dose and blood pressure remained lower than control levels for more than 10 hr.
Animal Model: Wistar rats (male, 6 weeks old initially, used 4 to 6 weeks after hyporeninemic DOCA/salt hypertension surgery, systolic blood pressure 160 to 240 mmHg)[3]
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: p.o.; single dose; daily for 2 weeks
Result: Induced a mild, consistent antihypertensive effect after single administration.
Reduced arterial blood pressure in a dose-related manner with repeated daily dosing, with no intensification of effect; the antihypertensive effect disappeared within 24 hr after each dose cessation.
Animal Model: Beagle dogs (male, 13 to 16 kg, used 2 to 5 weeks after 2-kidney, 1-clip renal hypertension surgery)[3]
Dosage: 0.3 mg/kg; 1 mg/kg
Administration: p.o.; single dose
Result: Induced a modest, long-lasting reduction in systemic blood pressure within 1 hr of administration, with effects persisting for more than 10 hr.
Lowered both systolic and diastolic blood pressure by about 40 mmHg at 1 mg/kg, and heart rate tended to increase (not statistically significant).
Animal Model: Sprague-Dawley rats (male, 300-400 g)[4]
Dosage: 0.03 mg/kg (i.v.); 0.3 mg/kg (i.v.); 3 mg/kg (p.o.); 10 mg/kg (p.o.)
Administration: i.v. or p.o.
Result: Induced maximum inhibition of angiotensin I (A-I) pressor response at 5 min, with longer lasting effects than enalaprilat at 0.03 mg/kg i.v.
Had a half-time of recovery (T1/2) of about 5 hr, and an ID50 of 0.07 mg/kg i.v. over a 7 hr observation period at 0.3 mg/kg i.v.
Augmented bradykinin (BK)-induced depressor response to -31.6 mmHg at 1 hr, -32.0 mmHg at 3 hr, -28.6 mmHg at 5 hr, and -24.8 mmHg at 7 hr at 3 mg/kg p.o.
Had an inhibitory effect on A-I pressor response lasting over 24 hr, with an ID50 of 1.8 mg/kg p.o. over a 24 hr observation period at 10 mg/kg p.o.
Animal Model: Beagle dogs (either sex, 13-15 kg)[4]
Dosage: 0.3 mg/kg; 1 mg/kg
Administration: p.o.
Result: Inhibited angiotensin I (A-I)-induced pressor response by over 90%, with prolonged inhibitory action compared to enalapril at 0.3 mg/kg p.o.
Inhibited A-I-induced pressor response by over 90%, with duration of action extending beyond 24 hr, while enalapril's effect at 1 mg/kg p.o. was no longer evident at 24 hr at 1 mg/kg p.o.
Molecular Weight

449.56

Formula

C22H31N3O5S
CAS No.
SMILES

OC(CN1C2=CC=CC=C2SC[C@@H](C1=O)N[C@H](C(O)=O)CCCCC3CCNCC3)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CV 5975 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CV 5975100277-62-1CV5975CV-5975Angiotensin-converting Enzyme (ACE)kidneyangiotensin Iplasmahypertensionaortabradykininrabbit lung ACEbrainspontaneously hypertensive ratsangiotensin converting enzymeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CV 5975
Cat. No.:
HY-182407
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.